Intellia’s (NTLA) CRISPR Therapies Show Promise Amid Competition Posted byZacks Equity Research December 31, 2021 Leave a comment on Intellia’s (NTLA) CRISPR Therapies Show Promise Amid Competition While Intellia’s (NTLA) pipeline is in early-stage clinical studies, its development is progressing well. Collaborations are a primary source of revenues in the absence of a marketed product.